Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

4.76USD
22 Sep 2017
Change (% chg)

$-0.09 (-1.86%)
Prev Close
$4.85
Open
$4.80
Day's High
$4.90
Day's Low
$4.55
Volume
259,322
Avg. Vol
226,573
52-wk High
$5.71
52-wk Low
$1.07

Latest Key Developments (Source: Significant Developments)

Verastem expands duvelisib development program to include peripheral T-cell lymphoma
Wednesday, 6 Sep 2017 06:05am EDT 

Sept 6 (Reuters) - Verastem Inc -:Verastem expands duvelisib development program to include peripheral T-cell lymphoma.Verastem Inc - ‍duvelisib receives fast track designation from FDA in PTCL; company to initiate a phase 2 clinical trial by year end 2017​.Verastem Inc - verastem expects that phase 2 study of duvelisib will be conducted in both U.S. and Japan.  Full Article

Verastem announces positive top-line data from the pivotal phase 3 Duo study
Wednesday, 6 Sep 2017 06:01am EDT 

Sept 6 (Reuters) - Verastem Inc :Verastem announces positive top-line data from the pivotal phase 3 Duo study in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.‍Plans to share clinical data from pivotal phase 3 Duo study​ with FDA with goal of filing new drug application during first half of 2018.  Full Article

Verastem Inc enters into an amendment to its sales agreement
Monday, 28 Aug 2017 06:05pm EDT 

Aug 28 (Reuters) - Verastem Inc ::Verastem Inc says entered into an amendment to its sales agreement, dated March 30 with Cantor Fitzgerald.Verastem Inc says under amendment, co increased offering price of shares of common stock that it may issue and sell to $75 million from $35 million .  Full Article

Verastem Q2 loss per share $0.36
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Verastem Inc :Verastem reports second quarter 2017 financial results.Q2 loss per share $0.36.Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Verastem Inc says expects to report top-line data from DUO study in latter part of summer 2017.  Full Article

Ridgeback Capital Investments reports 7.7 pct passive stake in Verastem
Thursday, 20 Jul 2017 04:50pm EDT 

July 20 (Reuters) - Verastem Inc :Ridgeback Capital Investments Lp reports a 7.7 percent passive stake in Verastem inc as of July 10, 2017 - sec filing.  Full Article

Verastem names Julie B. Feder as chief financial officer
Tuesday, 11 Jul 2017 04:05pm EDT 

July 11 (Reuters) - Verastem Inc ::Verastem names Julie B. Feder as chief financial officer.Verastem Inc - ‍feder joins Verastem from Clinton Health Access Initiative, Inc​.  Full Article

Verastem director Barberich buys 30,000 shares of co's common stock on May 15
Wednesday, 17 May 2017 08:28am EDT 

May 17 (Reuters) - Verastem Inc :Verastem Inc director Timothy Barberich reports purchase of 30,000 shares of co's common stock on May 15 at average price of $2.45 per share - SEC filing.  Full Article

Verastem Q1 loss per share $0.35
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - Verastem Inc ::Verastem reports first quarter 2017 financial results.Q1 loss per share $0.35.Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.  Full Article

Verastem reports year-end 2016 financial results
Thursday, 23 Mar 2017 04:01pm EDT 

Verastem Inc - : Verastem reports year-end 2016 financial results . Expect to have sufficient cash, cash equivalents and investments to fund our research and development programs and operations into 2018 . Net loss for year ended December 31, 2016 $0.99 per share .As of December 31, 2016, Verastem had cash, cash equivalents and investments of $80.9 million compared to $110.3 million as of December 31, 2015.  Full Article

Infinity expects net loss for 2017 in the range of $40 mln to $50 mln
Monday, 9 Jan 2017 08:03am EST 

Infinity Pharmaceuticals Inc : Infinity provides 2017 goals and financial guidance . Infinity Pharmaceuticals Inc - expects to end 2017 with a year-end cash and investments balance ranging from $40 million to $50 million . Infinity Pharmaceuticals Inc - expects net loss for 2017 to range from $40 million to $50 million. . Infinity Pharmaceuticals - updated cash runway expectation assumes receiving $6.0 million milestone payment from verastem for positive duo study results .Infinity Pharmaceuticals sees existing cash, cash equivalents, available-for-sale securities at Dec 31 2016 to be adequate to satisfy capital needs into Q1 2019.  Full Article

Verastem's blood cancer drug succeeds in late-stage trial

Verastem Inc said on Wednesday its drug to treat some types of blood cancer met the main goal of a late-stage study, sending the U.S. drug developer's shares up as much as 44.5 percent.